United States· US:52015-700_21c95e9f-0a3d-4fb8-90b5-934bad817d00

DIFICID

A fidaxomicin product containing fidaxomicin, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 16 of our 19 countries.

ATC A07AA12US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedDIFICIDATCA07AA12REGISTER NO.US:52015-700_21c95e9f…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Fidaxomicin is registered in 16 of 19 countries.

Countries holding a registration under ATC A07AA12 (fidaxomicin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Fidaxomicin · ATC A07AA12

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fidaxomicin costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Fidaxomicin · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$179.87
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
FIDAXOMICIN
Manufacturer
Merck Sharp & Dohme LLC
Country
United States (US)
ATC code
A07AA12
ATC class
Fidaxomicin
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    5201570022
    1 POUCH in 1 CARTON (52015-700-22) / 1 BOTTLE, GLASS in 1 POUCH (52015-700-23) / 150 mL in 1 BOTTLE, GLASS (52015-700-21)
  • ndc11
    52015-700-22

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

101 interactions on record for fidaxomicin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fidaxomicin · interactions on record

101 records

  • 3 severe
  • 24 moderate
  • 74 minor

Most severe, free to view

  • BerotralstatB06AC06severe
  • VenetoclaxL01XX52severe
  • RelugolixL02BX04severe
  • Sodium picosulfateA06AB08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fidaxomicin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fidaxomicin products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • France · Fidaxomicine Sun
  • United Kingdom (Northern Ireland) · Fidaxomicin Tillotts 200 Mg, Fidaxomicin Tillotts 40 Mg/Ml
  • Iceland · Dificlir
  • Liechtenstein · Dificlir, Dificlir 200 Mg
  • Norway · Dificlir, Dificlir 200 Mg
  • Sweden · Fidaxomicin Sun

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/831e09af-7c0e-4c9e-a1a1-5d4e426fda9b
GET /v1/drugs/831e09af-7c0e-4c9e-a1a1-5d4e426fda9b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "200",
  "substance": "FIDAXOMICIN",
  "productndc": "52015-700",
  "dosage_form": "GRANULE, FOR SUSPENSION",
  "dea_schedule": null,
  "strength_unit": "mg/5mL",
  "application_number": "NDA213138",
  "marketing_category": "NDA"
}

See everything about fidaxomicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.